
(Credit: Angiola Harry on Unsplash)
Breast Cancer Gene Mutations Vary, and Some Carry Moderate Risk
In A Nutshell
- Researchers found 70 BRCA2 mutations that only partly damage the gene, 34 of them most damaging.
- Those 34 roughly doubled breast cancer odds, far below the risk from classic mutations.
- Diagnoses came later, at an average age of 57 versus 51 in one dataset.
- No official guidelines exist yet, but the authors say carriers may need extra screening, not a mastectomy.
Women who carry a classic harmful mutation in BRCA2, a gene best known for its link to breast cancer, face a 69% lifetime chance of the disease. New research shows that number does not fit every BRCA2 mutation. A group of 34 mutations that only partly damage the gene appears to raise breast cancer risk by a moderate amount, well short of the danger tied to classic ones.
BRCA2 normally repairs broken DNA inside cells, which keeps damaged cells from turning cancerous. Classic harmful mutations act like a switch flipped off, wrecking that job almost entirely. Others behave more like a dimmer turned down. A team including Mayo Clinic researchers and scientists at three testing companies went looking for those weaker mutations and found 70 candidates, according to a study in Nature Communications.
Women carrying the 34 most damaging of those mutations were roughly twice as likely to have breast cancer as women without them, a result that held in two groups. Severe mutations in the same stretch of the gene carried about five to seven times the risk. Carriers of those 34 were diagnosed later than carriers of severe mutations, at an average age of 57 versus 51 in one dataset. Under established clinical guidelines, 14 of the 70 mutations were classified as “likely pathogenic,” a label that ClinVar, a public database of genetic variants, had given to only two.
Lab Tests Flagged 70 BRCA2 Mutations That Only Partly Break the Gene
Work began with a lab test that scores how well a changed copy of BRCA2 repairs DNA, from 1 (matching a known harmful mutation) to 5 (fully working). Researchers examined 535 gene changes, each swapping one building block of the BRCA2 protein for another within the stretch that grips DNA. Seventy landed in a middle zone. The 34 closest to broken were labeled strong partial mutations, and the other 36 weak.
To check those scores, the team edited the DNA of human cells that cannot survive without working BRCA2 and watched whether they lived. Survival matched the lab scores moderately well, and most of the 67 mutations tested produced middling survival rather than total failure.
Drug tests followed. Cells carrying 63 of those 67 partial mutations became more vulnerable to olaparib, a cancer drug that attacks cells with weak DNA repair, among them 31 of 32 strong ones. Whether patients’ tumors would respond the same way remains untested.
Strong Partial BRCA2 Mutations Raised Breast Cancer Risk Far Less Than Classic Ones
Myriad Genetics supplied results from adult women who had hereditary cancer testing between 2013 and 2025, about 185,000 with breast cancer and 931,000 without. Among them, 283 women carried one of 37 partial mutations. Results were adjusted for age, race and ethnicity, and personal and family cancer history.
Ambry Genetics compared its 376,778 women with breast cancer, tested between 2012 and 2024, with 182,015 women without the disease in a large public database. Eighty-nine Ambry patients carried one of 24 partial mutations.
Weak partial mutations showed no increase in risk at all. For the strong ones, the exact figures were 2.4 times the odds of breast cancer in the Myriad data and 2.1 times in the Ambry comparison.
A third dataset covered tumors. Foundation Medicine, a tumor-testing company, had analyzed 8,424 tumors from patients with many cancer types. Tumors with partial mutations appeared to have lost their healthy backup copy of BRCA2 in 36% of cases, between the 68% seen with classic harmful mutations and 20% with harmless changes. A DNA damage pattern typical of faulty repair landed in between, though only 25 tumors were compared.
Milder BRCA2 Mutations Could Mean Closer Screening, Not Mastectomy
No official guidelines exist yet for these mutations. Guidelines for classic BRCA2 mutations let women consider preventive mastectomy, which may be recommended once lifetime breast cancer risk tops 30% to 40%. For these partial mutations, the authors estimate a lifetime risk above 20% as a group, though figures for individual mutations remain unsettled. That level would qualify carriers for breast MRI alongside mammograms. Mastectomy may not be recommended, similar to how carriers of ATM and CHEK2, two other genes tied to moderate breast cancer risk, are managed.
Ovary removal, a separate surgery, follows a lower bar, around a 5% lifetime risk of ovarian cancer. Because classic BRCA2 mutations carry a high ovarian cancer risk, even a reduced risk from milder mutations could clear that line, so surgery might stay on the table. The study measured only breast cancer risk, and the authors call for more research on ovarian, prostate, and pancreatic cancers.
Today’s classification systems can flag a damaging BRCA2 mutation but cannot tell a partial one from a classic one, and many of these mutations had sat in public databases labeled uncertain. Lumping every damaging mutation together no longer fits the evidence. Sorting partial mutations from classic ones could eventually mean the difference between a mastectomy and a more measured plan built around closer screening, once larger studies confirm the risk for each individual mutation.
Disclaimer: This article summarizes one study for general information and is not medical advice. Anyone with concerns about genetic test results should consult a doctor or genetic counselor.
Paper Notes
Limitations
The 70 variants may not cover every partly working BRCA2 mutation. The lab work focused on DNA repair and cell survival, so other effects, such as how the protein protects DNA as it is copied, still need study, and most cell experiments used one cell type, HAP1, leaving tissue-specific effects untested. The Ambry comparison pitted women referred for testing against public databases of women without breast cancer, which could inflate risk estimates, though the Myriad analysis within a single testing cohort produced similar results. Individual mutations were too rare to study one by one, so researchers pooled them to estimate risk, and the penetrance (how often a mutation leads to disease) of each single variant needs larger studies. The paper measured only breast cancer risk, so ovarian, prostate, and pancreatic risks are unknown, and the lifetime breast cancer estimate of above 20% applies to the reduced-risk variants as a group. Tumor findings rested on small numbers, and it remains unknown whether tumors with these mutations respond to PARP inhibitors in patients.
Funding and Disclosures
The research was funded by NIH grants R35CA253187, R01CA304177, U24CA258058, and P50CA116201, along with support from the Breast Cancer Research Foundation, the BRCA research & cure alliance, and the Mayo Clinic Department of Laboratory Medicine and Pathology. Sixteen co-authors are employees of companies involved in the work: nine at Ambry Genetics, four at Myriad Genetics, and three at Foundation Medicine. All other co-authors declared no conflict of interest.
Publication Details
The paper, titled “Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants,” was published in Nature Communications, 2026, Volume 17, Article 11570, after being received July 25, 2025, and accepted October 15, 2026. Authors are Huaizhi Huang, Chunling Hu, Jie Na, Lisa N. Heppler, Andrew Goldfarb, Matthew Kucera, Timothy Simmons, Kevin L. Peterson, Olivia K. Rossman, Steven N. Hart, Rohan David Gnanaolivu, Amik Munankarmy, Mohamed Abozaid, Jamie D. Weyandt, Christen M. Csuy, Christina A. Seelaus, Colin C. Young, Kelly Fulk, Zahra Heidari, Paulo Cilas Morais Lyra, Ronan E. Couch, Benjamin Persons, Yen Y. Tan, Katherine L. Nathanson, Tuya Pal, Erin Mundt, Rachid Karam, Tina Pesaran, Siddhartha Yadav, Susan M. Domchek, Alvaro N. A. Monteiro, Scott H. Kaufmann, Nicholas Boddicker, Wenan Chen, Elisha Hughes, Marcy E. Richardson, Brennan Decker, and Fergus J. Couch, who is the corresponding author ([email protected]) at Mayo Clinic in Rochester, Minnesota. DOI: https://doi.org/10.1038/s41467-026-79433-5







